EUVIMEDEUVIMED entdecken
Crossref

Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them

Fhasal Alam

Harvard Undergraduate Health Policy Review · 2024 · 24 (1)

DOI: 10.56927/897463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Harvard Undergraduate Health Policy Review, 2024. Verfasst von Fhasal Alam.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The conversation surrounding prescription weight-loss medications, or “anti-obesity” drugs, has skyrocketed amidst new developments. Wegovy and Ozempic, two weight-loss drugs that recently entered the market, have given patients in the United States the tools to control their weight—perhaps without

Zitieren

APA

Alam, F. (2024). Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them. Harvard Undergraduate Health Policy Review, 24(1). https://doi.org/10.56927/897463

Vancouver

Alam F. Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them. Harvard Undergraduate Health Policy Review. 2024;24(1). doi:10.56927/897463

BibTeX
@article{Alam2024,
  author = {Alam, Fhasal},
  title = {Weight-Loss “Anti-Obesity” Medications Remain Inaccessible to Demographics Who Truly Need Them},
  journal = {Harvard Undergraduate Health Policy Review},
  year = {2024},
  volume = {24},
  number = {1},
  doi = {10.56927/897463}
}
Kostenlos starten →